and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC, a new bioscience company dedicated to developing ... PhD (Co-Founder & CEO), a former senior executive at AbbVie with expertise ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

The company plans to analyze the data to determine next steps. AbbVie shares fell as much as 13% as of 11:15 a.m. in New York, their biggest intraday drop since March 2020. The stock had gained 29 ...

Here's how this drugmaker proved the bears wrong, and why that means it's worth investing $1,500 in today. Read More: Earn up ...

Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two mid-stage studies. Truist says that Abbvie’s “pain” is ...

JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the emraclidine Phase 2 data “was certainly disappointing ...

Even before today's trial results, AbbVie lost ground after the U.S. FDA approved Bristol Myers Squibb's (BMY) Cobenfy (xanomeline and trospium chloride) in September as a new schizophrenia treatment.

The company plans to analyze the data to determine next steps. AbbVie shares fell as much as 13% as of 11:15 a.m. in New York, their biggest intraday drop since March 2020. The stock had gained 29% ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

The best-case scenario would be AbbVie determining the study conduct was not proper and that it decides to start a new trial, but even this scenario results in a setback of several years and a ...

The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...